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ABSTRACT
INTRODUCTION: Retinoids are natural and synthetic compounds part of the family of polyisoprenoid lip-
ids. These compounds are involved in several important physiological processes in the human body because 
of their ability to bind to different nuclear receptors. Retinoids are used in the therapy of some precancer-
ous lesions, the treatment of acute promyelocytic leukemia (APL), T-cell lymphoma, and the prevention of 
malignancies in high-risk cancer groups. In this work we discuss the possibilities for analysis of the newly 
synthesized hydrazone of the retinoid bexarotene. 
AIM: The purpose of this study is to conduct FTIR spectral analysis of newly synthesized hydrazone of bex-
arotene.
MATERIALS AND METHODS: Infrared spectra 500-4000 cm-1 were taken on a Bruker FTIR spectrometer 
using ATR - a plug with Smart iTR adapter.
RESULTS: The infrared spectra of the newly synthesized compound were strikingly similar in the relative 
positions and intensities of the resulting peaks, confirming its close structural relationship with bexaro-
tene. Despite the structural similarity, there were significant differences that point to the introduction of a 
substituent and the formation of a new hydrazone derivative.
CONCLUSION: In order to confirm the data obtained by FTIR spectroscopy, a further reversed-phase HPLC-
UV analysis of the new hydrazone derivative should be performed.
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INTRODUCTION
Retinoids are synthetic derivatives of natural 
vitamin A. Their structure includes lipophilic iso-
prenoids and a linear chain with a hydrophilic end 
group. Retinoids exert their effects by binding with a 
group of nuclear retinoic acid receptors (RARs) and 
retinoid X receptors (RXRs) which act as ligand-acti-
vated transcription regulators for specific genes (1,2). 
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The ligands of the nuclear receptors are small mole-
cules that can be modified by drug design and in this 
way to achieve drugs for the treatment of underlying 
diseases, including oncological diseases, osteoporo-
sis, and diabetes (3,4). 
Studies investigating the therapeutic use of reti-
noids date back to the 1970s. 
Retinoids have a very wide range of applica-
tions, which includes their use as cosmetic agents 
and effective pharmaceuticals for skin diseases. Fur-
thermore, some retinoids are undergoing clinical tri-
als for the treatment of breast, lung, and colon cancer 
and other diseases caused by uncontrolled cell pro-
liferation (5). More recently, it has been shown that 
treatment with RXR agonists, such as bexarotene, 
leads to pathological and behavioral improvements 
in transgenic mouse models of Alzheimer’s disease 
(6). However, retinoid use leads to many serious side 
effects. The most serious of these is that the family 
of retinoid compounds consists of the most potent 
teratogens known. Teratogens are compounds the 
use of which during the specific periods of pregnan-
cy may cause severe birth defects. Other side effects 
result of retinoid use include irritation of the tissues 
treated, which can be so severe that patients cannot 
tolerate treatment.
The main structure of the retinoid compounds 
is shown in Fig. 1.
Retinoids are subjected to clinical trials in can-
cer treatments both as monotherapy (7,8) and in 
combination with other drugs. Combination thera-
py allows a reduction in the effective concentration 
of retinoids, which reduces their toxicity and the pro-
cess of retinoid resistance (9,10). Additionally, reti-
noid activity may increase neoplastic tissue sensitiv-
ity to other agents such as chemotherapy and epigen-
etic drugs. 
There are many reasons to explore novel RXR 
agonists that may decrease or avoid the primary side 
effects to treatment with bexarotene, including hy-
perlipidemia, hypothyroidism, and cutaneous toxici-
ty, as well as expand the range of therapy (11,12).
Bexarotene is synthetic retinoid compounds in-
dicated for the treatment of cutaneous manifesta-
tions of cutaneous T-cell lymphoma. Nowadays the 
group of retinoids, including bexarotene, are of great 
interest due to the wide range of their application.
Infrared spectroscopy (IR spectroscopy or vi-
brational spectroscopy) involves the interaction of 
infrared radiation with matter. It is one of the most 
important analytic techniques and is mostly based 
on absorption spectroscopy (13). Infrared spectros-
copy is an easy and reliable technique widely used 
for the qualitative characterization of newly obtained 
compounds.
Hydrazone derivate was synthesized and its 
structure was confirmed by his spectral data. To de-
termine the newly obtained structure a detailed anal-
ysis of the FT-IR spectra was performed. We ana-
lyzed the starting compound for synthesis - bexaro-
tene, its methyl ester, and the newly synthesized hy-
drazone analog. Analysis of the compounds was per-
formed in the range 4000-500 cm-1.
AIM
The present study considers determining the 
newly obtained structure of bexarotene hydrazone. 
In order to prove the structure of the newly obtained 
compound, a comparative ATR-FTIR analysis of the 
spectra of the starting compound - bexarotene, its 
methyl ester, and the newly synthesized Bexarotene 
derivative in the range 4000-500 cm-1 was performed.
MATERIALS AND METHODS
Bexarotene (99.99%, Fluorochem); methyl alco-
hol (99.99%, HPLC grade, Fisher Chemical), 4-iso-
propyl benzaldehyde (99.99%, HPLC grade, Fisher 
Chemical), water (HPLC grade, Fisher Chemical), 
formic acid (99-100% A.R., CHEM-LAB)
Infrared spectra 500-4000 cm-1 were taken on a 
Bruker FT-IR spectrometer using ATR - a plug with 
Smart iTR adapter.
Fig. 1. The main structure of the retinoid compounds
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RESULTS AND DISCUSSION 
The newly obtained hydrazone of bexarotene 
and isopropylbenzaldehyde was synthesized accord-
ing to the described methodology (14). 
Infrared spectroscopy is one of the main in-
strumental methods for determining the identi-
ty and characterization of newly synthesized com-
pounds. To perform analysis by infrared spectrosco-
py, a method of direct spectrum recording using an 
ATR with a Smart iTR adapter is used.
The newly obtained hydrazone of bexarotene 
and 4-isopropyl benzaldehyde is shown in Fig. 2.
The spectra of the test compounds are similar 
in all analyzed regions of uptake, with several char-
acteristic features resulting from the presence of 
structural similarities common to bexarotene and 
the newly obtained derivative. 
ATR-FTIR spectra of the bexarotene, its meth-
yl ester, and 4-isopropyl-phenyl-methylidene-4-[1-
(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl) 
ethenyl] benzohydrazide are presented in Fig. 3.
In the recorded spectra in the range from 3000 
to 2800 cm– 1, the extremely high similarity in the ab-
sorption signals is observed. The obtained bands are 
close in location and intensity of the reported max-
ima. This is explained by the fact that in this area 
there are some characteristic oscillations of the ben-
zene nuclei, as well as symmetrical and asymmetric 
vibrations of the CH bonds.
In the analysis, the slightly intensive bands in 
the interval 2000-1660 cm-1 were observed. They are 
characteristic of the presence of a benzene nucleus in 
the structure.
The most significant difference in the two con-
sidered spectra is observed in the range from 1620 to 
1720 cm–1, where the presence of a medium-intensity 
band is reported in the spectrum of the methyl ester. 
The presence of an ester functional and the deforma-
tion oscillations characteristic of the C=O bond are 
reported in the region of the spectrum between 1730 
and 1715 cm– 1.
In the spectrum of the newly synthesized com-
pound, the presence of a medium-intensity pro-
nounced peak with a maximum at 1109 cm–1 is im-
pressive. This assumption is further confirmed by 
the fact that such a band is not present in the spectra 
of bexarotene and its methyl ester.
CONCLUSION
Numerous studies have led to the development 
of a large number of methods for the synthesis of ret-
inoids. More and more structurally diverse analogs 
of these natural compounds have emerged, making 
this aspect of retinoid chemistry difficult to summa-
rize. The reason for this is precisely the constant de-
mand for structures that target and selectively affect 
nuclear receptors, as well as to reduce the number of 
adverse reactions inherent in natural retinoids. In 
connection with the possibility of synthesis of nov-
el derivatives, it is especially important to develop a 
fast, precise, and accurate method for quality analy-
sis of the obtained products
Fig. 2. Structure of 4-isopropyl-phenyl-methylidene-4-[1-
(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl) ethe-
nyl] benzohydrazide - hydrazone of bexarotene and 4-iso-
propyl benzaldehyde
Fig. 3. ATR-FTIR spectra of the test compounds
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The infrared spectrum of the newly synthesized 
compound is strikingly similar in the relative posi-
tions and intensities of the resulting peaks, confirm-
ing its close structural relationship with Bexarotene. 
This is mainly due to the present bexarotene skele-
ton containing three nuclei and the associated meth-
yl radicals. Despite the structural similarity, there are 
significant differences that point to the introduction 
of a substituent and the formation of a new hydra-
zone derivative.
In order to confirm the data obtained by FT-IR 
spectroscopy, it is to be carried out to conduct a re-
versed-phase HPLC-UV analysis of the new bexaro-
tene hydrazone derivative.
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